Shots:

• Preliminary results from P-II study & a sub-study analysis showed stronger T-cell responses and increase antibody after receiving Ad26.COV2.S as booster dose 6 mos after BNT162B2 2-dose regimen
• This P-II (COV2008) study conducted where total 1540 participants will be recruited to receive booster dose of Ad26.COV2.S with 5, 2.5, or 1x1010 vp doses. J&J plans to assess effects of booster dose on omicron variants as well
• This P-II data is supported by prelim. results of P-II (COV-BOOST) study published in The Lancet, which showed after two doses of either BNT162b2 (n=106) or ChAdOx1 nCov-19 (n=108), a booster dose of the J&J’s (Ad26.COV2.S) increased both antibody and T-cell responses

Ref: J&J | Image: J&J